|Bid||0.0000 x 1300|
|Ask||0.0000 x 800|
|Day's Range||2.5700 - 2.6800|
|52 Week Range||1.6500 - 7.1500|
|Beta (5Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO), (OTCQX: HCANF), (Germany: A9KN) today announced its financial and operational results for three months ending March 31, 2021 ("Q1 2021"). The Company reported record revenues of $9.9 million for Q1 2021, a 123% increase compared to the previous year. This included the sale of over 5.2 million grams of cannabis products principally to dispensaries in Oregon and California, a 253% year over year increase. Organic revenuei growth was 62%, the highest organic growth recorded in the Company's history. The Company also reported a gross profit of $2.0 million, an increase from $(172.2k) for the three months ended March 31, 2020 ("Q1 2020"). The adjusted gross profit was $2.2 million (compared to $117.4k in Q1 2020). The reported gross margin in Q1 2021 was 19.7% in comparison with -3.9% in Q1 2020. Complete results are reported in the Company's consolidated financial statements for the three months ended March 31, 2021 (the "Consolidated Financial Statements") and associated management's discussion and analysis (the "Q1 2021 MD&A").
Cellect Biotechnology Ltd (NASDAQ: APOP) has announced data from the Phase 1/2 study in Israel evaluating ApoGraft technology for Graft versus Host Disease (GvHD), a severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). All eleven patients enrolled for the trial were transplanted using the ApoGraft product and were engrafted on time. The primary objective, safety, and tolerability of ApoGraft administered to patients with hemato-oncology disorders was met, and no procedure-related adverse events were reported during the study. ApoGraft functionally selects cells to improve the safety and efficacy of regenerative medicine and cell therapies. Last month, the company announced a reverse merger agreement with a privately held Quoin Pharmaceuticals. The new entity will be listed on NASDAQ under the symbol 'QNRX.' Price Action: APOP shares are down 6.69% at $2.37 on the last check Monday. See more from BenzingaClick here for options trades from BenzingaOvid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological ConditionsHumanigen's Lenzilumab Shows Encouraging Response Rate In Blood Cancer Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Results Support Ongoing Clinical Development of ApoGraft in U.S.Tel Aviv, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today announced positive data from the Company's open label Phase 1/2 clinical trial of its ApoGraft™ technology in Israel. All eleven patients enrolled for the trial were transplanted using the ApoGraft product and were engrafted in a timely manner. The primary objective, safety and tolerability of ApoGraft administered to patients with hemato-oncology disorders, was met and there were no procedure related adverse events (AEs) reported during the course of the study. As previously announced last month, following the anticipated closing of the merger with Quoin Pharmaceuticals, the development of the ApoGraft technology is expected to be pursued by San-Diego based EnCellX, led by Adi Mohanty. “The data validates earlier results and supports the ongoing development of our products,” commented Dr. Shai Yarkoni, Chief Executive Officer. “I remain committed and believe that the human data from this study will expedite the clinical development of the ApoGraft.” About Cellect Biotechnology Ltd. Cellect Biotechnology (APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of cell-based therapies. The Company's technology is expected to provide researchers, clinicians and pharmaceutical companies with the tools to rapidly isolate specific cells in quantity and quality, allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment. Forward Looking Statements This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; or maintain its current operations; uncertainties involving any strategic transaction the Company may decide to enter into as the result of its current efforts to explore new strategic alternatives; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC. ContactCellect Biotechnology Ltd.Eyal Leibovitz, Chief Financial Officerwww.cellect.co+972-9-974-1444Or EVC Group LLC Michael Polyviou(732) email@example.com